Indeed, the disruption of CD47-SIRPα signaling was demonstrated to lead to tumor regression through mechanisms such as promoting phagocytic uptake of tumor cells by macrophages and increasing antigen presentation by DCs, thereby stimulating anti-tumor adaptive immune responses [116]. The gene discussed is SIRPA; the disease is neoplasm.